Outcome MeasureMystical Experience

CEQ

Challenging Experience Questionnaire

7 Papers in Blossom

About This Instrument

The Challenging Experience Questionnaire (CEQ) is a 26-item self-report measure developed by Frederick Barrett and colleagues at Johns Hopkins University to assess the occurrence and intensity of difficult or challenging experiences during psychedelic sessions. It measures seven domains: grief, fear, death, insanity, isolation, physical distress, and paranoia. Each item is rated on a 0–5 scale (0 = none, 5 = extreme), with scores expressed as a percentage of maximum. The CEQ is an important safety and characterization measure in psychedelic clinical trials, as challenging experiences (commonly called ‘bad trips’) can occur even in controlled settings and may impact therapeutic outcomes. Interestingly, research has shown that moderate challenging experiences, when well-supported, can sometimes contribute positively to therapeutic outcomes. The CEQ helps researchers and clinicians quantify and contextualize these experiences.

Outcome Data Across Studies

Reported results for CEQ across 6 studies with quantitative data.

Outcome data across 11 study arm–timepoint observations
SD
Set and Setting: A Randomized Study of Different Musical Genres in Supporting Psychedelic Therapy
2020Secondary
Psilocybin-assisted(experimental)0100.30.2
Set and Setting: A Randomized Study of Different Musical Genres in Supporting Psychedelic Therapy
2020Secondary
Psilocybin-assisted(experimental)0100.30.2
Set and Setting: A Randomized Study of Different Musical Genres in Supporting Psychedelic Therapy
2020Secondary
Psilocybin-assisted(experimental)5640.30.2
Set and Setting: A Randomized Study of Different Musical Genres in Supporting Psychedelic Therapy
2020Secondary
Psilocybin-assisted(experimental)5660.30.1
Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial
2023Exploratory
Medium dose psilocybin(experimental)0.251528.918.6<.001
Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial
2023Exploratory
Placebo(inactive)0.25199.68.7<.001
Psilocybin-assisted therapy for demoralisation in hospice patients: feasibility, safety and preliminary efficacy
2025Safety
PATH(experimental)0.3331036.620.8
Single-Dose Psilocybin for Depression With Severe Treatment Resistance: An Open-Label Trial
2025Exploratory
Psilocybin(experimental)11255.0
Single-Dose Psilocybin for Depression With Severe Treatment Resistance: An Open-Label Trial
2025Exploratory
Psilocybin(experimental)211250.0
A phase 1 study of a second experience with Group Retreat Psilocybin Therapy for partial responders after a first experience
2026Secondary
Psilocybin group therapy(experimental)313

Papers Using CEQ

Quick Facts

Full Name
Challenging Experience Questionnaire
Domain
Mystical Experience
Papers Indexed
7
Score Range
0100
Interpretation
Lower = better
Unit
percentage
All Measures